Exelixis, INC Form 4 insider transactions

Dana Aftab, CSO/EVP of Discovery & Translational Research at Exelixis, exercised stock options and sold shares on November 5, 2024, according to a Form 4 filing with the SEC.

Jeffrey Hessekiel, EVP & General Counsel of Exelixis, sold 50,000 shares of common stock on November 1, 2024, at an average price of $34.13, according to a Form 4 filing.

Director George Poste sold 30,000 shares of Exelixis, Inc. common stock at an average price of $34 per share on November 1, 2024.

Exelixis CEO Michael Morrissey reported gifting 46,000 shares of Exelixis common stock to a donor advised fund on October 31, 2024.

Dana Aftab, CSO/EVP of Discovery & Translational Research at Exelixis, sold 1,162 shares of common stock on October 30, 2024, under a pre-arranged 10b5-1 trading plan.

Jeffrey Hessekiel, EVP & General Counsel of Exelixis, sold 25,000 shares of common stock at an average price of $28.39 on October 28, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Patrick J. Haley, EVP, Commercial at Exelixis, exercised a stock option for 100,000 shares and disposed of 96,111 shares to cover the exercise price and tax obligations.

Exelixis CEO Michael Morrissey exercised stock options, resulting in the acquisition and disposal of shares, and gifted shares to a family trust.

Jeffrey Hessekiel, EVP & General Counsel of Exelixis, Inc., sold 25,000 shares of common stock at an average price of $26.38 on September 23, 2024, according to a Form 4 filing.

Jeffrey Hessekiel, EVP, General Counsel & Secretary of Exelixis, exercised options and sold 20,000 shares of common stock on August 26, 2024, according to a Form 4 filing.

Director Maria C Freire sold 8,250 shares of Exelixis, Inc. common stock at a price of $26.56 on August 14, 2024.

Julie Smith, a director at Exelixis, Inc., reported a transfer of 4,682 shares of common stock to her ex-spouse as part of a settlement agreement.

Dana Aftab, CSO of Exelixis, Inc., recently sold 20,883 shares of common stock at an average price of $27.06.

Director George Poste sold 33,725 shares of Exelixis, Inc. common stock at an average price of $26.89 on August 8, 2024.

Dana Aftab, CSO/EVP of Discovery & Translational Research at Exelixis, exercised stock options and sold 95,000 shares of common stock on August 7, 2024, according to a Form 4 filing with the SEC.

Patrick J. Haley, EVP, Commercial at Exelixis, sold 14,000 shares of common stock at $25.50 per share under a pre-arranged 10b5-1 trading plan.

Jeffrey Hessekiel, EVP, General Counsel & Secretary of Exelixis, exercised stock options and sold 80,000 shares of common stock on August 7, 2024, according to a Form 4 filing.

Christopher J. Senner, EVP and CFO of Exelixis, exercised options to acquire 125,000 shares of common stock and simultaneously sold the same amount on August 9, 2024.

Director Jack L. Wyszomierski sold 8,287 shares of Exelixis, Inc. common stock at an average price of $22 per share, according to a Form 4 filing with the SEC.

Director Stelios Papadopoulos received 18,838 restricted stock units (RSUs) from Exelixis, Inc. on May 31, 2024, according to a Form 4 filing.

Director George Poste acquired 18,838 shares of Exelixis common stock through restricted stock units (RSUs) on May 31, 2024.

Director Maria C. Freire reported the acquisition of restricted stock units (RSUs) and holdings of Exelixis, Inc. common stock.

Director Tomas J. Heyman reports acquisition of restricted stock units and disposal of common stock related to RSU vesting.

Director Bob Oliver reports acquisition of 18,838 restricted stock units and disposal of 37,014 common stock shares.

Director Jack L. Wyszomierski reports acquisition of restricted stock units in Exelixis, Inc.

Director Sue Gail Eckhardt reports the acquisition of 18,838 restricted stock units and disposal of 34,262 shares of Exelixis common stock.

Director Mary C Beckerle received 18,838 restricted stock units and disposed of 34,262 shares of Exelixis common stock on May 31, 2024.

Director Julie Smith reports acquisition of stock and option awards in Exelixis, Inc.

David Johnson, a director at Exelixis, acquired options to purchase 42,767 shares of common stock at an exercise price of $21.69, according to a recent SEC Form 4 filing.

David Johnson, a director of Exelixis, and Caligan Partners LP have increased their holdings in Exelixis through recent stock purchases.